Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas

Tomotaka Shimura, Yuichiro Tada, Hideaki Hirai, Daisuke Kawakita, Satoshi Kano, Kiyoaki Tsukahara, Akira Shimizu, Soichiro Takase, Yorihisa Imanishi, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Yukiko Sato, Chihiro Fushimi, Hideaki Takahashi, Takuro Okada, Hiroki Sato, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro SakaiKoji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Mizuo Ando, Shinji Kohsaka, Toyoyuki Hanazawa, Hideaki Chazono, Yoshiyuki Kadokura, Hitome Kobayashi, Toshitaka Nagao

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The molecular characteristics of therapeutically-relevant targets and their clinicopathological implications in salivary duct carcinomas (SDCs) are poorly understood. We investigated the gene alterations and the immunoexpression of crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, in order of frequency, were as follows: TP53, 68%; PIK3CA, 18%; H-RAS, 16%; BRAF, 4%; and AKT1, 1.5%. PIK3CA/H-RAS/BRAF mutations were more common in de novo SDC than in SDC ex-pleomorphic adenoma. Furthermore, these mutations were mutually exclusive for HER2 overexpression/amplification. TP53 mutations were frequently detected in cases with the aberrant p53 expression, and TP53 missense and truncating mutations were associated with p53-extreme positivity and negativity, respectively. DISH analysis revealed no cases of EGFR amplification. The rates of PI3K, p-Akt, and p-mTOR positivity were 34%, 22%, and 66%, respectively; PTEN loss was observed in 47% of the cases. These expressions were correlated according to the signaling axis. Cases with PI3K negativity and PTEN loss appeared to show a lower expression of androgen receptor. In the multivariate analysis, patients with SDC harboring TP53 truncating mutations showed shorter progression-free survival. Conversely, p-Akt positivity was associated with a favorable outcome. This study might provide information that leads to advances in personized therapy for SDC.

Original languageEnglish
Pages (from-to)1852-1867
Number of pages16
JournalOncotarget
Volume9
Issue number2
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Salivary Ducts
Carcinoma
Gene Expression
Mutation
Phosphatidylinositol 3-Kinases
Pleomorphic Adenoma
Androgen Receptors
Mutation Rate
Missense Mutation
Disease-Free Survival
Multivariate Analysis
Genes

Keywords

  • H-RAS
  • PI3K/Akt signaling pathway
  • PIK3CA
  • Salivary duct carcinoma
  • TP53

ASJC Scopus subject areas

  • Oncology

Cite this

Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. / Shimura, Tomotaka; Tada, Yuichiro; Hirai, Hideaki; Kawakita, Daisuke; Kano, Satoshi; Tsukahara, Kiyoaki; Shimizu, Akira; Takase, Soichiro; Imanishi, Yorihisa; Ozawa, Hiroyuki; Okami, Kenji; Sato, Yuichiro; Sato, Yukiko; Fushimi, Chihiro; Takahashi, Hideaki; Okada, Takuro; Sato, Hiroki; Otsuka, Kuninori; Watanabe, Yoshihiro; Sakai, Akihiro; Ebisumoto, Koji; Togashi, Takafumi; Ueki, Yushi; Ota, Hisayuki; Ando, Mizuo; Kohsaka, Shinji; Hanazawa, Toyoyuki; Chazono, Hideaki; Kadokura, Yoshiyuki; Kobayashi, Hitome; Nagao, Toshitaka.

In: Oncotarget, Vol. 9, No. 2, 01.01.2018, p. 1852-1867.

Research output: Contribution to journalArticle

Shimura, T, Tada, Y, Hirai, H, Kawakita, D, Kano, S, Tsukahara, K, Shimizu, A, Takase, S, Imanishi, Y, Ozawa, H, Okami, K, Sato, Y, Sato, Y, Fushimi, C, Takahashi, H, Okada, T, Sato, H, Otsuka, K, Watanabe, Y, Sakai, A, Ebisumoto, K, Togashi, T, Ueki, Y, Ota, H, Ando, M, Kohsaka, S, Hanazawa, T, Chazono, H, Kadokura, Y, Kobayashi, H & Nagao, T 2018, 'Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas', Oncotarget, vol. 9, no. 2, pp. 1852-1867. https://doi.org/10.18632/oncotarget.22927
Shimura, Tomotaka ; Tada, Yuichiro ; Hirai, Hideaki ; Kawakita, Daisuke ; Kano, Satoshi ; Tsukahara, Kiyoaki ; Shimizu, Akira ; Takase, Soichiro ; Imanishi, Yorihisa ; Ozawa, Hiroyuki ; Okami, Kenji ; Sato, Yuichiro ; Sato, Yukiko ; Fushimi, Chihiro ; Takahashi, Hideaki ; Okada, Takuro ; Sato, Hiroki ; Otsuka, Kuninori ; Watanabe, Yoshihiro ; Sakai, Akihiro ; Ebisumoto, Koji ; Togashi, Takafumi ; Ueki, Yushi ; Ota, Hisayuki ; Ando, Mizuo ; Kohsaka, Shinji ; Hanazawa, Toyoyuki ; Chazono, Hideaki ; Kadokura, Yoshiyuki ; Kobayashi, Hitome ; Nagao, Toshitaka. / Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. In: Oncotarget. 2018 ; Vol. 9, No. 2. pp. 1852-1867.
@article{b5faeee80f2d464c82afa729fee18b82,
title = "Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas",
abstract = "The molecular characteristics of therapeutically-relevant targets and their clinicopathological implications in salivary duct carcinomas (SDCs) are poorly understood. We investigated the gene alterations and the immunoexpression of crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, in order of frequency, were as follows: TP53, 68{\%}; PIK3CA, 18{\%}; H-RAS, 16{\%}; BRAF, 4{\%}; and AKT1, 1.5{\%}. PIK3CA/H-RAS/BRAF mutations were more common in de novo SDC than in SDC ex-pleomorphic adenoma. Furthermore, these mutations were mutually exclusive for HER2 overexpression/amplification. TP53 mutations were frequently detected in cases with the aberrant p53 expression, and TP53 missense and truncating mutations were associated with p53-extreme positivity and negativity, respectively. DISH analysis revealed no cases of EGFR amplification. The rates of PI3K, p-Akt, and p-mTOR positivity were 34{\%}, 22{\%}, and 66{\%}, respectively; PTEN loss was observed in 47{\%} of the cases. These expressions were correlated according to the signaling axis. Cases with PI3K negativity and PTEN loss appeared to show a lower expression of androgen receptor. In the multivariate analysis, patients with SDC harboring TP53 truncating mutations showed shorter progression-free survival. Conversely, p-Akt positivity was associated with a favorable outcome. This study might provide information that leads to advances in personized therapy for SDC.",
keywords = "H-RAS, PI3K/Akt signaling pathway, PIK3CA, Salivary duct carcinoma, TP53",
author = "Tomotaka Shimura and Yuichiro Tada and Hideaki Hirai and Daisuke Kawakita and Satoshi Kano and Kiyoaki Tsukahara and Akira Shimizu and Soichiro Takase and Yorihisa Imanishi and Hiroyuki Ozawa and Kenji Okami and Yuichiro Sato and Yukiko Sato and Chihiro Fushimi and Hideaki Takahashi and Takuro Okada and Hiroki Sato and Kuninori Otsuka and Yoshihiro Watanabe and Akihiro Sakai and Koji Ebisumoto and Takafumi Togashi and Yushi Ueki and Hisayuki Ota and Mizuo Ando and Shinji Kohsaka and Toyoyuki Hanazawa and Hideaki Chazono and Yoshiyuki Kadokura and Hitome Kobayashi and Toshitaka Nagao",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22927",
language = "English",
volume = "9",
pages = "1852--1867",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "2",

}

TY - JOUR

T1 - Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas

AU - Shimura, Tomotaka

AU - Tada, Yuichiro

AU - Hirai, Hideaki

AU - Kawakita, Daisuke

AU - Kano, Satoshi

AU - Tsukahara, Kiyoaki

AU - Shimizu, Akira

AU - Takase, Soichiro

AU - Imanishi, Yorihisa

AU - Ozawa, Hiroyuki

AU - Okami, Kenji

AU - Sato, Yuichiro

AU - Sato, Yukiko

AU - Fushimi, Chihiro

AU - Takahashi, Hideaki

AU - Okada, Takuro

AU - Sato, Hiroki

AU - Otsuka, Kuninori

AU - Watanabe, Yoshihiro

AU - Sakai, Akihiro

AU - Ebisumoto, Koji

AU - Togashi, Takafumi

AU - Ueki, Yushi

AU - Ota, Hisayuki

AU - Ando, Mizuo

AU - Kohsaka, Shinji

AU - Hanazawa, Toyoyuki

AU - Chazono, Hideaki

AU - Kadokura, Yoshiyuki

AU - Kobayashi, Hitome

AU - Nagao, Toshitaka

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The molecular characteristics of therapeutically-relevant targets and their clinicopathological implications in salivary duct carcinomas (SDCs) are poorly understood. We investigated the gene alterations and the immunoexpression of crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, in order of frequency, were as follows: TP53, 68%; PIK3CA, 18%; H-RAS, 16%; BRAF, 4%; and AKT1, 1.5%. PIK3CA/H-RAS/BRAF mutations were more common in de novo SDC than in SDC ex-pleomorphic adenoma. Furthermore, these mutations were mutually exclusive for HER2 overexpression/amplification. TP53 mutations were frequently detected in cases with the aberrant p53 expression, and TP53 missense and truncating mutations were associated with p53-extreme positivity and negativity, respectively. DISH analysis revealed no cases of EGFR amplification. The rates of PI3K, p-Akt, and p-mTOR positivity were 34%, 22%, and 66%, respectively; PTEN loss was observed in 47% of the cases. These expressions were correlated according to the signaling axis. Cases with PI3K negativity and PTEN loss appeared to show a lower expression of androgen receptor. In the multivariate analysis, patients with SDC harboring TP53 truncating mutations showed shorter progression-free survival. Conversely, p-Akt positivity was associated with a favorable outcome. This study might provide information that leads to advances in personized therapy for SDC.

AB - The molecular characteristics of therapeutically-relevant targets and their clinicopathological implications in salivary duct carcinomas (SDCs) are poorly understood. We investigated the gene alterations and the immunoexpression of crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, in order of frequency, were as follows: TP53, 68%; PIK3CA, 18%; H-RAS, 16%; BRAF, 4%; and AKT1, 1.5%. PIK3CA/H-RAS/BRAF mutations were more common in de novo SDC than in SDC ex-pleomorphic adenoma. Furthermore, these mutations were mutually exclusive for HER2 overexpression/amplification. TP53 mutations were frequently detected in cases with the aberrant p53 expression, and TP53 missense and truncating mutations were associated with p53-extreme positivity and negativity, respectively. DISH analysis revealed no cases of EGFR amplification. The rates of PI3K, p-Akt, and p-mTOR positivity were 34%, 22%, and 66%, respectively; PTEN loss was observed in 47% of the cases. These expressions were correlated according to the signaling axis. Cases with PI3K negativity and PTEN loss appeared to show a lower expression of androgen receptor. In the multivariate analysis, patients with SDC harboring TP53 truncating mutations showed shorter progression-free survival. Conversely, p-Akt positivity was associated with a favorable outcome. This study might provide information that leads to advances in personized therapy for SDC.

KW - H-RAS

KW - PI3K/Akt signaling pathway

KW - PIK3CA

KW - Salivary duct carcinoma

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=85040008564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040008564&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22927

DO - 10.18632/oncotarget.22927

M3 - Article

AN - SCOPUS:85040008564

VL - 9

SP - 1852

EP - 1867

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 2

ER -